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Relationship between Plasma Fibroblast Growth Factor-23
Concentration and Survival Time in Cats with Chronic Kidney
Disease
R.F. Geddes, J. Elliott, and H.M. Syme
Background: Fibroblast growth factor-23 (FGF-23) and parathyroid hormone (PTH) are commonly increased in cats with
azotemic chronic kidney disease (CKD). Both are predictors of survival time in human patients, but these relationships have
not previously been examined in the cat.
Objectives: To investigate the relationship between plasma FGF-23 and PTH concentrations at diagnosis of CKD in cats
with survival time and with disease progression over 12 months.
Animals: 214 azotemic, client-owned cats (≥9 years).
Methods: Retrospective study: Biochemical and urinary variables at diagnosis of azotemic CKD, including plasma FGF-
23 and PTH concentrations were assessed as predictors of survival time (all-cause mortality) using Cox regression, and as
predictors of CKD progression over 12 months using logistic regression.
Results: In the final multivariable Cox regression model, survival was negatively associated with plasma creatinine
(P = .002) and FGF-23 concentrations (P = .014), urine protein-to-creatinine ratio (P < .001) and age (P < .001). Survival
was positively associated with PCV (P = .004). In the final multivariable logistic regression model, independent predictors of
CKD progression included logFGF-23 and age. Neither plasma phosphate nor PTH was found to be an independent predic-
tor of survival time or of CKD progression.
Conclusions and Clinical Importance: Plasma FGF-23 concentration is a novel prognostic indicator in cats with CKD,
independent of other factors including plasma creatinine and phosphate concentrations. Further work is required to assess if
FGF-23 contributes directly to CKD progression, but regardless these findings may make FGF-23 a useful biomarker for
predicting poorer outcomes in cats with CKD.
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Chronic kidney disease (CKD) in cats is highlyprevalent; 31% of cats over 15 years of age have
azotemic CKD1 and there is evidence of CKD in 60.4%
of cats, with a prevalence of 80.9% in cats over
15 years of age.2 CKD causes severe morbidity and
mortality, with renal disorders being the most common
cause of mortality in cats ≥5 years of age in the UK,
accounting for 13.6% of deaths.3
The syndrome of the clinical, biochemical and imag-
ing abnormalities that are correlated with CKD and
renal osteodystrophy is termed “chronic kidney disease-
mineral and bone disorders” (CKD-MBD).4 Develop-
ment of CKD-MBD is considered to be a consequence
of reduced Glomerular Filtration Rate (GFR), and
associated phosphate retention. Calcium-phosphate (Ca-
P) derangements appear prevalent in cats with CKD;
with the most common biochemical derangement previ-
ously documented to be hyperparathyroidism, occurring
in 84% of azotemic cats.5 Additionally, the phospha-
tonin fibroblast growth factor-23 (FGF-23) has been
demonstrated to increase with advancing International
Renal Interest Society (IRIS) stage of CKD and to be
further increased in cats with higher plasma phosphate
concentrations.6
FGF-23 is secreted primarily by osteocytes7 and
osteoblasts,8,9 in response to hyperphosphatemia and
increased plasma calcitriol concentrations.10 FGF-23
acts in the kidney to inhibit calcitriol production by
reducing mRNA expression of the vitamin D synthesis
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enzyme (25-hydroxyvitamin D-1a-hydroxylase) and to
increase phosphaturia by down-regulating sodium-phos-
phorus type II co-transporters (NaPi-IIa and NaPi-IIc)
in the proximal tubules.11 It also acts in the parathyroid
gland to decrease parathyroid hormone (PTH) produc-
tion and secretion.12
Plasma FGF-23 concentrations in human patients are
an independent predictor of progression of CKD13 and
are independently associated with case fatality in
patients starting haemodialysis for CKD.14 Additionally,
very high levels of PTH are associated with increased
risk of death in CKD patients on hemodialysis.15 Plasma
phosphate concentration is an independent predictor of
survival time,16,17 and progression18 in cats with CKD,
however, no previous studies have examined the rela-
tionship between plasma PTH or FGF-23 concentration
and CKD progression or survival time in cats.
To explore the impact of CKD-MBD in cats the aim
of this study was to examine if plasma FGF-23 or PTH
concentration at diagnosis of azotemic CKD were inde-
pendent predictors of progression of the disease over
the following 12 months, and of survival time.
Materials and Methods
Case Selection
Records from 2 London-based first opinion practices between
7th January 1992 and 1st September 2011 were reviewed and cats
≥9 years of age with renal azotemia were identified. The majority
of these cases had been included in a previous study.18 The date of
diagnosis of renal azotemia was defined as the date that a plasma
creatinine concentration >2.0 mg/dL and a concurrent urine speci-
fic gravity (USG) <1.035 were documented. The Ethics and Welfare
Committee of the Royal Veterinary College had approved the
study protocol and informed consent was obtained from all own-
ers. Biochemical analyses and measurement of plasma total thyrox-
ine were performed at an external laboratory on the date samples
were obtained.a Urine samples collected by cystocentesis and previ-
ously stored at 80°C were used for batch analysis of urine pro-
tein-to-creatinine ratio (UPC) at an external laboratory.a UPC
measurements from samples with urinary tract infections (identified
by the presence of active urine sediment on microscopy and con-
firmed by bacterial cultureb) were not included in any analyses.
Cases required residual stored frozen EDTA plasma samples to
be available for measurement of FGF–23 and PTH. Cases were
excluded if they were already being fed a renal diet at diagnosis as
this can result in a reduction in plasma FGF-23 and PTH concen-
trations.19 Cases that demonstrated USG > 1.035 following diag-
nosis were excluded and those with concurrent hyperthyroidism,
or that developed hyperthyroidism during follow-up. Cats were
excluded if they had evidence of other concurrent disease, except
systemic hypertension, or were taking medications that alter cal-
cium or phosphate absorption or metabolism. All owners were
advised to feed a commercially available renal diet after diagnosis
of CKD. Other medications were prescribed as necessary on an
individual case basis. No attempt was made to account for man-
agement strategies in the analyses.
Measurement of PTH and FGF-23
EDTA plasma samples previously stored at 80°C were used
for batch analysis of PTH and FGF-23. The samples had been
stored in 0.5 mL aliquots that had not undergone any freeze-thaw
cycles in the majority of cases. In a small number of cases aliquots
used to measure FGF-23 had undergone1 freeze-thaw cycle, which
has previously been shown not to significantly affect feline FGF-
23 concentrations.6 PTH concentrations were measured using a
validated total intact PTH immunoradiometric assay,c as previ-
ously described.20 Samples with a PTH concentration below the
lower limit of detection (<5.2 pg/mL)20 were assigned a value of
2.6 pg/mL. Intact plasma FGF-23 concentrations were measured
using a validated ELISAd as previously described.6
Statistical Analysis
Survival times using all-cause mortality were calculated from
the date of diagnosis of azotemic CKD to the date of death or
euthanasia. Date of death was assigned as the 15th of the month
if the exact date was unknown. Cases still alive on 1st January
2013 or lost to follow-up were censored. Survival times were com-
pared between groups using a Mann-Whitney U-test.
Progression of CKD was defined as an increase of >25% in
plasma creatinine during the 12 months after the date of diagnosis of
azotemic CKD. Cases were classified as stable if they were followed-
up for a minimum of 12 months, without an increase of >25% in
plasma creatinine concentration. Cases followed-up for <12 months
were censored unless they demonstrated CKD progression. Renal
follow-up was defined as the time from date of diagnosis of azotemic
CKD to the date of the last available plasma creatinine concentra-
tion. Blood and urine samples were routinely taken approximately
every 16 weeks, or sooner if it was deemed clinically necessary.
Statistics were performed using SPSS.e Results are reported as
median [25th, 75th percentiles] and significance was determined as
P < .05. Available data for the following variables obtained at the
time of CKD diagnosis were included in analyses: plasma crea-
tinine, phosphate, total calcium, PTH, FGF-23, potassium, total
protein, globulin, albumin and cholesterol concentrations, packed
cell volume (PCV), USG, UPC, age, presence of a urinary tract
infection (UTI) and a diagnosis of hypertension (systolic blood
pressure [SBP] >160 mmHg with evidence of concurrent hyperten-
sive retinopathy or SBP > 170 mmHg on 2 separate occasions).
Variables associated with survival time were examined using
Cox regression models. Variables were recoded into categorical
variables if they did not meet the assumption of proportional haz-
ards, assessed by inspection of Kaplan-Meier curves. Categorical
variables were assigned based on biologically relevant cutpoints
where possible or otherwise by terciles. Variables that were signifi-
cantly associated with survival time at the 10% level were included
in a backwards conditional multivariable Cox regression model.
Variables associated with CKD progression were examined
using binary logistic regression models. FGF-23 and PTH were
logarithmically transformed because of their highly skewed distri-
butions. USG values were subjected to removal of the one before
the decimal point and multiplied by 1,000 to allow interpretation
of odds ratio (OR). UPC values were multiplied by 10 to allow
interpretation of OR. To allow the inclusion of variables of partic-
ular interest, variables significant at the 20% level in the univari-
able analyses were carried into a backwards conditional
multivariable binary logistic regression model to determine inde-
pendent predictors of progression.
No attempt was made to impute missing data or to assess inter-
actions because of the large number of variables in the models.
Results
Survival Analysis
A total of 722 cats with a diagnosis of azotemic
CKD were identified. Cases were excluded for the fol-
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lowing reasons: a diagnosis of hyperthyroidism
(n = 233), no sample available for measurement of
FGF-23 and PTH (n = 272), no urine sample taken on
date of diagnosis (n = 2) and a diagnosis of nephrotic
syndrome with atypical disease pathology (n = 1). This
left 214 cats available for inclusion in the survival anal-
ysis. The majority (n = 180) were nonpedigree domestic
cats, but there were 13 Persian or Persian crosses, 10
Burmese or Burmese crosses, 3 Tiffany, 2 British short-
hair, 2 Chinchilla and one of each of the following:
American shorthair, Ocicat, Siamese and Russian Blue
cross. Ninety-nine cats were female (one entire, 98 neu-
tered) and 115 were male (2 entire, 113 neutered). UPC
measurements were performed in 174 cases, the remain-
ing cases either had a UTI or no urine sample was
available in storage.
The median age at diagnosis was 14.4 [11.0, 16.0]
years. Seven cats were acquired as adults and their
age was unknown. One hundred and sixty cats
(74.8%) had died or were euthanized at or before the
end of the follow-up period (1st January 2013) with a
median survival time of 327 [109, 646] days. Fifty-
four cats were either still alive at the study end point
(33) or were lost to follow-up (21) and were censored
from the analysis. The median follow-up time for
censored cases was 658 [282, 919] days. Follow-up
time was significantly longer in the censored cases
compared to cases that died or were euthanized
(P < .001).
Variables associated with survival time at the 10%
level (P < .1) in univariable Cox regression analyses are
shown in Table 1 and were included in the multivari-
able model. PCV was considered as a continuous vari-
able as it met the assumption of proportional hazards.
For FGF-23 and phosphate 4 categories were used for
the analysis based on biologically relevant cutpoints, for
other variables 3 biologically relevant cutpoints or ter-
ciles (for age, albumin and USG) were used. A Kaplan-
Meier curve of survival using plasma FGF-23 concen-
tration at diagnosis of CKD is shown in Figure 1. In
the final multivariable model (Table 2), survival was
negatively associated with plasma creatinine (P = .002)
and FGF-23 concentrations (P = .014), UPC (P < .001)
and age (P < .001). Survival was positively associated
with PCV (P = .004).
Progression Analysis
Of the 214 cases available for inclusion in this study,
148 (69.2%) cases were classified as IRIS stage 2 at
Table 1. Univariable Cox regression analysis of factors associated with survival (all-cause mortality) at the 10%
level (P < .1) at diagnosis of azotemic chronic kidney disease.
Variable n
Survival Time by Cutpoints (Days)
Median [25th, 75th Percentiles] P Value HR 95% CI for HR
Creatinine (≤2.8 mg/dL) 148 490 [208, 836] <.001
>2.8–5.0 55 263 [42, 657] .068 1.39 0.975–1.99
>5.0 11 20 [2, 108] <.001 10.7 5.45–21.0
Phosphate (≤4.5 mg/dL) 99 462 [200, 812] <.001
4.5–5.0 26 708 [333, 976] .16 0.679 0.394–1.17
5.0–6.0 37 343 [186, 875] .55 1.14 0.737–1.77
>6.0 52 98 [18, 502] <.001 1.99 1.36–2.92
USG (>1.020) 67 586 [207, 840] .020
≤1.016 79 318 [54, 628] .005 1.75 1.18–2.60
1.017–1.020 68 365 [131, 848] .092 1.42 0.994–2.13
UPC (<0.2) 95 544 [280, 905] <.001
0.2–0.4 51 246 [67, 705] <.001 2.07 1.38–3.10
>0.4 28 126 [31, 464] <.001 2.63 1.63–4.26
FGF23 (≤700 pg/mL) 100 577 [289, 895] <.001
>700–3,000 69 354 [168, 734] .53 1.13 0.777–1.64
>3,000–10,000 24 277 [65, 632] .003 2.08 1.29–3.36
>10,000 21 38 [10, 152] <.001 7.40 4.35–12.6
PTH (≤17.6 pg/mL) 110 377 [158, 873] .026
>17.6–30 40 570 [172, 909] .15 0.714 0.454–1.12
>30 64 261 [50, 601] .076 1.38 0.968–1.96
PCV (%) 213 NA <.001 0.911 0.885–0.937
Albumin (>3.21 g/dL) 71 546 [161, 880] .010
≤2.95 72 255 [70, 581] .003 1.81 1.23–2.67
2.96–3.21 71 394 [211, 705] .21 1.29 0.866–1.93
Age (≤12.7 years) 69 484 [138, 928] <.001
12.7–15.4 69 587 [231, 910] .39 1.19 0.795–1.79
>15.4 69 236 [109, 506] <.001 2.29 1.58–3.60
Normotensive cases 164 423 [126, 840]
Diagnosis of hypertension 50 310 [181, 608] .004 1.68 1.18–2.37
n, number of cats in group; HR, hazard ratio; CI, confidence interval; NA, not applicable.
For continuous variables, the hazard ratio represents the effect of a unit change in the predictor variable on the frequency of the out-
come (death).
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diagnosis, 55 (25.7%) were stage 3, and 11 (5.1%) were
stage 4. Of the stage 2 cases, 106 (71.6%) remained in
stage 2 during renal follow-up, 39 (26.4%) reached
stage 3, and 3 (2.0%) reached stage 4. Of the stage 3
cases, 48 (87.3%) remained in stage 3 during renal fol-
low-up and 7 (12.7%) reached stage 4.
One hundred and nine cats (50.9%) did not demon-
strate progression but were followed-up for less than
12 months and were therefore censored from the pro-
gression analysis. In the remaining 105 cats, 38 cases
(36.2%) demonstrated CKD progression during the ini-
tial 12 month follow-up period and 67 cases (63.8%)
did not demonstrate progression of CKD but were fol-
lowed-up for a minimum of 12 months and were there-
fore classified as stable. Renal follow-up was 277 [144,
399] days for progressive cases, 742 [539, 1001] days for
stable cases and 56 [0, 147] days for censored cases.
Summary statistics for clinicopathological variables for
progressive, stable and censored cases taken on the date
of diagnosis of CKD are shown in Table 3.
Variables associated with CKD progression within
12 months at the 20% level (P < .2) in univariable
logistic regression analyses are shown in Table 4. In the
final multivariable model, independent predictors of
CKD progression within 12 months of diagnosis
included logFGF-23 and age (Table 5). An increase in
age of 1 year was associated with an increase in the
odds of progression of 21% and a 1 unit increase in
logFGF-23 (or a 10-fold increase in plasma FGF-23
concentration) was associated with an increase in the
odds of progression of 289%.
Discussion
This study examined if plasma FGF-23 or PTH con-
centration are associated with disease progression and
survival time in cats with azotemic CKD. Plasma FGF-
23 concentration, but not plasma PTH or phosphate
concentrations was found to be independently associ-
ated with survival time using all-cause mortality and to
be an independent predictor of progression of CKD
over 12 months.
CKD-MBD is thought to cause damage to renal tis-
sue and contribute to disease progression, although the
mechanisms involved are not completely understood.
Phosphate might have direct deleterious effects on the
kidney by causing nephrocalcinosis,21 and indirect
effects by initiating CKD-MBD development. Plasma
phosphate concentration is independently associated
with risk of death in a meta-analysis of human CKD
patients,22 and to be an independent predictor of sur-
vival time16,17 in cats with CKD. In the present study,
plasma phosphate was associated with survival time in
univariable analyses, but was not an independent pre-
dictor of survival time when FGF-23 was also included.
In a previous study, plasma phosphate concentration at
CKD diagnosis was an independent predictor of CKD
progression in cats,18 but this result was not replicated
in the present study. This might be because of the dif-
ferences in the severity of CKD in each study popula-
tion, with a smaller proportion of IRIS stage 3 and 4
cases in the present study versus the previous study
(25% [26/105] versus 38% [81/213]). Since phosphate
retention increases as GFR declines, having a greater
proportion of cases in the higher IRIS stages would
Fig 1. Kaplan-Meier curve for survival of cats (n = 214) based
on plasma fibroblast growth factor-23 (FGF-23) concentration at
diagnosis of chronic kidney disease. Cats with baseline plasma
FGF-23 > 10,000 pg/mL (P = .003) and 3,000–10,000 pg/mL
(P < .001), but not 700–3,000 pg/mL (P = .53) had significantly
shorter survival times than cats with FGF-23 within the reference
interval at baseline (≥700 pg/mL). Censored individuals are repre-
sented by ticks.
Table 2. Multivariable Cox regression analysis of fac-
tors associated with survival time (all-cause mortality)







PCV (%) 0.060 0.021 .004 0.942 0.904–0.981
Creatinine
(≤2.8 mg/dL) .002
>2.8–5.0 0.378 0.231 .10 1.46 0.927–2.30
>5.0 1.71 0.478 <.001 5.50 2.16–14.0
UPC (<0.2) <.001
0.2–0.4 0.789 0.221 <.001 2.20 1.43–3.39
>0.4 0.965 0.325 .003 2.62 1.39–4.96
Age (≤12.7 years) <.001
12.7–15.4 0.702 0.271 .010 2.02 1.19–3.43
>15.4 1.53 0.271 <.001 4.63 2.72–7.88
FGF23
(≤700 pg/mL) .014
>700–3,000 0.042 0.233 .86 1.04 0.660–1.65
>3,000–10,000 0.668 0.333 .045 1.95 1.02–3.74
>10,000 1.36 0.458 .003 3.91 1.59–9.58
b, coefficient; SE, standard error; HR, hazard ratio; CI, confi-
dence interval.
Variables significant at the 10% level in univariable analyses
were included in this model to determine independent predictors
of survival time (all-cause mortality). For continuous variables,
the hazard ratio represents the effect of a unit change in the pre-
dictor variable on the frequency of the outcome (death).
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have included more cats with hyperphosphatemia in the
previous study. Comparison of plasma phosphate con-
centrations reveals that these values are very similar in
both studies for the stable cases (4.4 [3.6, 5.1] versus 4.4
[3.6, 5.2]), but lower in this study for the progressive
cases (4.7 [3.8, 8.0] versus 5.1 [4.0, 6.8]), which might
account for why phosphate was not associated with
progression in this study.
PTH was a predictor of survival time in univariable
analyses in this study, but was not found to be an inde-
pendent predictor of mortality in the multivariable
model. In human patients, high levels of PTH are asso-
ciated with an increased risk of death in CKD patients
on hemodialysis;15 however, this result has not been
consistent in all studies and a meta-analysis did not
demonstrate a consistent association between death and
serum PTH concentration in CKD patients of varying
stages.22 This study examined the association between
PTH and survival time or CKD progression in the cat.
Plasma PTH is increased in nonazotemic cats that
develop azotemia within 12 months, compared to cats
that remain nonazotemic (plasma creatinine ≤1.6 mg/
dL).23 It is likely that PTH was increased in the cats
that went on to develop azotemic CKD to help main-
tain normal plasma phosphate concentrations in the
face of a reduced GFR. What could not be determined
from this association study was whether PTH was con-
tributing to CKD progression in these cats or acting as
a biomarker for reduced renal function. PTH is consid-
ered to act as a uremic toxin because of its effects on
bone remodeling and the heart and vasculature.24
Whether increased PTH can directly contribute to CKD
progression remains to be demonstrated, but the present
study suggests that its use as a biomarker for more pro-
gressive CKD in the cat is limited. The only variable
involved in Ca-P homeostasis that was independently
Table 3. Summary statistics for baseline clinicopathological variables for cats with stable or progressive chronic
kidney disease over the following 12 months.
Variable Stable (n = 67) Progressive (n = 38) Short Follow-Up (n = 109)
Creatinine (mg/dL) 2.4 [2.2, 2.8] 2.5 [2.3, 2.9] 2.5 [2.3, 3.6]
Urea (mg/dL) 47.6 [40.0, 56] 50.7 [44.8, 66.1] 53.5 [42.6, 78.7]
USG 1.020 [1.016, 1.024] 1.017 [1.014, 1.026] 1.018 [1.016, 1.021]
UPC 0.14 [0.07, 0.21] 0.20 [0.14, 0.39] 0.23 [0.14, 0.36]
Phosphate (mg/dL) 4.4 [3.6, 5.1] 4.7 [3.8, 8.0] 5.1 [4.0, 6.7]
FGF-23 (pg/mL) 504.3 [340.3, 1291.2] 1243.2 [555.6, 2066.5] 1103.8 [414.1, 3977.4]
PTH (pg/mL) 13.8 [5.8, 26.6] 19.2 [7.0, 32.7] 17.8 [7.8, 45.9]
Potassium (mEq/L) 4.0 [3.7, 4.3] 4.1 [3.8. 4.2] 4.0 [3.7, 4.4]
T. Calcium (mg/dL) 10.1 [9.76, 10.5] 9.96 [9.6, 10.4] 10.1 [9.72, 10.52]
Total Protein (g/dL) 7.83 [7.47, 8.28] 7.91 [7.53, 8.45] 7.67 [7.25, 8.27]
Globulin (g/dL) 4.66 [4.31, 5.02] 4.75 [4.32, 5.54] 4.58 [4.18, 5.26]
Albumin (g/dL) 3.14 [2.97, 3.32] 3.09 [2.81, 3.25] 3.07 [2.81, 3.24]
Cholesterol (mg/dL) 205 [158, 251] 185 [162, 250] 197 [154, 236]
PCV (%) 35 [32, 37] 32 [29, 38] 32 [27, 36]
SBP (mmHg) 142 [127, 154] 154 [130, 174] 141 [126, 160]
% with hypertension 18 39 21
% with UTI 16 8 7
Age (years) 13 [11, 15] 15 [12, 16] 15 [11, 17]
Weight 4.13 [3.54, 4.88] 3.80 [3.10, 4.60] 3.4 [2.8, 4.2]
% male 58 58 50
Follow-up (days) 742 [539, 1001] 277 [144, 399] 56 [0, 147]
Year of diagnosis 2008 [2005, 2010] 2007 [2003, 2009] 2008 [2005, 2010]
Data presented as Median [25th, 75th percentile] or prevalence (%).
Table 4. Univariable binary logistic regression analysis
of baseline variables associated with progression of
chronic kidney disease (CKD) over 12 months at the
20% level (P < .2).
Variable n OR with 95% CI P Value
Diagnosis of hypertension 105 2.989 [1.213, 7.365] .017
LogFGF-23 (pg/mL) 105 2.657 [1.183, 5.967] .018
USG 9 1000 105 0.925 [0.858, 0.998] .043
PCV (%) 105 0.925 [0.854, 1.002] .055
UPC 9 10 88 1.128 [0.982,1.296] .088
Albumin (g/dL) 105 0.333 [0.082, 1.353] .12
Age (years) 97 1.122 [0.969, 1.301] .13
Phosphate (mg/dL) 105 1.207 [0.936, 1.556] .15
Creatinine (mg/d/L) 105 1.54 [0.806, 2.93] .19
The odds ratio indicates the increase in the odds of CKD pro-
gressing for each unit increase in the explanatory variable.
Table 5. Multivariable binary logistic regression analy-
sis of baseline variables associated with progression of
chronic kidney disease (CKD) over 12 months (n = 84).
Variable Odds Ratio with 95% CI P Value
Log (FGF-23 pg/mL) 3.89 [1.27, 11.9] .017
Age (years) 1.21 [1.001, 1.45] .049
The odds ratio indicates the increase in the odds of CKD pro-
gressing for each unit increase in the explanatory variable.
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associated with survival time and CKD progression in
this study was plasma FGF-23 concentration.
Plasma FGF-23 increases early in the course of CKD,
before the development of overt hyperphosphatemia,25
where it acts to increase the fractional excretion of phos-
phate in remaining nephrons. It has been shown to be
increased in cats that go on to develop azotemia within
12 months, compared to those remaining nonazotemic.26
Feline plasma FGF-23 concentration is therefore likely
to better reflect total body phosphate retention during
mild to moderate CKD than plasma phosphate concen-
tration, which may explain firstly, why an association
between FGF-23 and CKD progression was identified
when an association between phosphate and CKD pro-
gression was not and secondly, why including FGF-23
in the survival analysis resulted in the exclusion of phos-
phate from the multivariable model.
A clear concentration-dependent relationship between
plasma FGF-23 concentration and survival time was
found in this study, where highly increased FGF-23
concentrations (>10,000 pg/mL) were associated with an
almost 4-times increase in risk of death. Additionally, a
10-fold increase in FGF-23 concentration at diagnosis
was associated with a 289% increase in the odds of
feline CKD progression over the next 12 months. These
effects were independent of plasma creatinine concentra-
tion, suggesting that derangements in Ca-P homeostasis
are important contributors to morbidity and mortality
in all stages of azotemic CKD.
FGF-23 predicts the progression of CKD in human
patients,13,27,28 and FGF-23 concentrations are also well
established as being independently associated with case
fatality in CKD patients at the start of hemodialy-
sis,14,29 and in earlier stages of CKD.27,28 At present,
just as has been debated for many years concerning
PTH, it is unclear whether FGF-23 is a uremic toxin,
or whether it is a surrogate marker for other causes of
uremic toxicity. Recent evidence suggests that in
humans, FGF-23 can induce left ventricular hypertro-
phy,30 and is an independent predictor of myocardial
infarction, stroke, and cardiovascular mortality in CKD
patients.27 However, although these findings may shed
some light on how FGF-23 may act as a uremic toxin
in human patients, cardiovascular incidents are not a
commonly recognized cause of death or euthanasia in
feline CKD patients. It has been demonstrated retro-
spectively that plasma FGF-23 concentrations can be
reduced in feline CKD patients by feeding a phosphate
restricted diet.19 Further work is now required to
explore why FGF-23 is associated with CKD progres-
sion in cats and if targeted reduction of FGF-23 can
improve survival time.
In this study, age was an independent predictor of
survival time and of progression of CKD, with an
increase of 1 year in age at diagnosis of CKD associ-
ated with a 21% increase in the risk of progression over
the next 12 months. An association between age and
survival time is not a novel finding,31 and makes sense
biologically. Aging is associated with a decreased ability
to repair and regenerate the kidney32 and renal
histopathologic changes are observed with increasing
frequency in older cats.33 Aged rodent kidneys develop
significantly more interstitial fibrosis post-reperfusion
than young kidneys, despite normal aged kidneys hav-
ing no interstitial fibrosis.34 Therefore, it is possible that
any injury to the kidney in an older cat could lead to
an exaggerated repair response and a more progressive
form of CKD.
Median survival time for cats in this study was 367
[147, 813] days, which is similar to other reports in the
literature.16,31,35 Plasma creatinine concentration, UPC,
and PCV were independent predictors of all-cause mor-
tality in the present study. Plasma creatinine concentra-
tion was found to be associated with survival time in
this, and in previous studies of cats with CKD,17,31,36
and median survival times for each IRIS stage in this
study are similar to those reported previously.16,37 UPC
has previously been shown to be an independent predic-
tor of survival time in cats with CKD,31 and in this
study being classified as borderline proteinuric (UPC
0.2–0.4) or proteinuric (UPC > 0.4) under the IRIS pro-
teinuria classification schemef was associated with a
greater than 2-times increase in risk of death. A previ-
ous study found UPC to be an independent predictor of
progression of CKD;18 however, UPC did not remain
in the multivariable model in the present analysis. A
placebo-controlled interventional study failed to demon-
strate a significant increase in survival time when feline
CKD patients with proteinuria were administered an
angiotensin converting enzyme (ACE) inhibitor, despite
a significant lowering of UPC with treatment.38 The
role of proteinuria in progression of CKD is therefore
currently unclear.
PCV or hematocrit has previously been found to be
significantly associated with survival time in univariable
analyses36 and found to be associated with death within
1 month for cats with CKD.17 PCV is not an indepen-
dent predictor of survival time, although it has been
linked to CKD progression in stage 2 cats, but not
when cats in all stages were considered together.18 No
attempt was made to examine the cats in IRIS stages 2
and 3 separately in the present study, because there
were only 9 cases in IRIS stage 3 that demonstrated
progression. Anemia of CKD is considered to be multi-
factorial, but in part a result of decreased erythropoi-
etin production by the kidney.39 Although few cases in
this study were anemic, with a median PCV of 33% [30,
37], as PCV decreases there will be a reduction in the
oxygen carrying capacity of the blood, which in the dis-
eased kidney might result in hypoxia. One marker of
hypoxia, urinary vascular endothelial growth factor, has
been associated with shorter survival times and progres-
sion in feline CKD,40 therefore it is possible that small
changes in PCV might exacerbate CKD and shorten
survival time through hypoxia.
There were a number of limitations in this study.
Cases might not have had a blood sample taken at the
time of death or euthanasia, therefore some of the cats
might have progressed without it being documented.
Additionally, plasma creatinine concentration was used
as a marker for GFR, which is dependent on muscle
mass; therefore changes in muscle mass might have
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resulted in cats being identified as stable that actually
had a substantial change in their GFR. Furthermore, all-
cause mortality was used in the survival analysis, with a
large number of cats being euthanized. There might have
been circumstances in which owners elected for euthana-
sia for reasons other than severe retractable illness,
which will have introduced some bias into the analysis.
In summary, increased FGF-23 at diagnosis of CKD
is associated with an increased risk of progression of
the disease over the next 12 months and associated with
an increased risk of death. These findings might make it
a useful biomarker for predicting poorer outcomes in
cats with CKD. Further work is now required to eluci-
date the complex relationships between variables
involved in Ca-P derangements in CKD and to estab-
lish if FGF-23 is a mediator, or simply a marker of
CKD-MBD in cats.
Footnotes
a Idexx laboratories, Wetherby, UK
b Performed at the Royal Veterinary College Diagnostic Labora-
tory Services, Hatfield, UK
c Total intact PTH immunoradiometric assay – coated bead ver-
sion, 3KG600, Scantibodies, Santee, CA
d FGF-23 ELISA Kit, Kainos Laboratories, Tokyo, Japan
e IBM SPSS Statistics 21, Armonk, NY
f www.iris-kidney.com
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